Abstract 616P
Background
REG and TAS are approved for the treatment of refractory mCRC. However, data on their sequential use in any setting is limited. The aim of this study was to describe the characteristics and clinical outcomes of patients (pts) with mCRC treated sequentially in community clinical practice in the USA.
Methods
This was a retrospective cohort study using the nationwide de-identified Flatiron Health electronic health record-derived database. Pts aged ≥18 years at mCRC diagnosis treated sequentially with REG and TAS±Bev from Jan 2015 to Sep 2022 were divided into two cohorts: R-T (REG followed by TAS±Bev) and T-R (TAS±Bev followed by REG). Index date was the initiation of the first therapy in a sequence. Minimum follow up was 3 months (mos). Clinical outcomes included overall survival (OS), time to treatment discontinuation (TTD), neutropenia, and use of granulocyte-colony stimulating factor (G-CSF).
Results
A total of 818 pts were included (n=393 R-T; n=425 T-R). Most pts received index therapy in 3L (41.9%) or 4L (23.7%). Baseline characteristics were similar between cohorts (Table). Median OS improved with R-T vs T-R in both 3L and 4L (13.1 vs 11.5 mos in 3L; 11.6 vs 10.3 mos in 4L), though the differences were not statistically significant (HR [95% CI]: 0.94 [0.74, 1.19] 3L; 0.86 [0.63, 1.18] 4L). TTD was slightly longer with R-T vs T-R in 3L (8.7 vs 8.1 mos, HR 0.91 [0.73, 1.14]) and 4L (8.5 vs 7.9 mos, HR 0.86 [0.63, 1.16]). Frequency of neutropenia and use of G-CSF were lower with R-T vs T-R (38.9% vs 48.0% neutropenia; 14.0% vs 17.9% G-CSF).
Table: 616P
n (%) | R-T n = 393 | T-R n = 425 |
Median age (IQR), years | 63 (56, 70) | 63 (56, 72) |
Male gender | 233 (59.3) | 227 (53.4) |
Race White Black or African American Asian | 241 (61.3) 64 (16.3) 19 (4.8) | 270 (63.5) 54 (12.7) 16 (3.8) |
Stage IV mCRC at diagnosis | 217 (55.2) | 237 (55.8) |
ECOG PS 0/1 | 278 (70.7) | 300 (70.6) |
KRAS mut | 183 (46.6) | 194 (45.6) |
BRAF mut | 5 (1.3) | 19 (4.5) |
Line of index treatment 1 2 3 4 ≥5 | 26 (6.6) 67 (17.0) 167 (42.5) 87 (22.1) 46 (11.7) | 27 (6.4) 67 (15.8) 176 (41.4) 107 (25.2) 48 (11.3) |
Median months since mCRC diagnosis (IQR) | 24.6 (16.6, 35.7) | 24.5 (17.3, 36.0) |
Prior anti-EGFR | 131 (33.3) | 153 (36.0) |
Prior bevacizumab | 308 (78.4) | 337 (79.3) |
TAS+Bev | 45 (11.5) | 63 (14.8) |
Neutropenia | 15 (3.8) | 9 (2.1) |
Prior G-CSF | 198 (50.4) | 227 (53.4) |
Conclusions
This real-world study showed that pts treated with sequential R-T vs T-R appeared to have longer OS and TTD, and less neutropenia and G-CSF use. Sequential therapy starting with REG may provide a chemotherapy break to improve tolerability and reduce myelosuppression in pts with refractory mCRC.
Clinical trial identification
Editorial acknowledgement
Editorial assistance in the preparation of this abstract was provided by Open Health Scientific Communications, London UK, with financial support from Bayer.
Legal entity responsible for the study
The authors.
Funding
Bayer.
Disclosure
T. Bekaii-Saab: Financial Interests, Institutional, Advisory Board: Bayer, Pfizer, Incyte, Ipsen, Seattle Genetics, Genentech, Merck KGA, Merus, Eisai, Servier; Financial Interests, Institutional, Other, DSMB: Merck; Financial Interests, Personal, Advisory Board: AbbVie, Boehringer Ingelheim, Janssen, AstraZeneca, Daiichi Sankyo, Natera, Celularity, Exact Science, Sobi, BeiGene, Xilis, Foundation Medicine, Stemline, Blueprint, Celularity, Caladrius, GSK, Deciphera, Zai Labs, Illumina, Sanofi; Financial Interests, Personal, Other, DSMB: AstraZeneca, Exelixis, The Valley Hospital, Fibrogen; Financial Interests, Personal, Other, DSMC: PanCAN; Financial Interests, Personal, Royalties, WO/2018/183488: HUMAN PD1 PEPTIDE Vaccines and Uses Thereof – Licensed to Imugene: Imugene; Financial Interests, Personal, Royalties, WO/2019/055687: Methods and Compositions for the Treatment of Cancer Cachexia – Licensed to Recursion: Recursion; Financial Interests, Institutional, Research Grant: Agios, Arys, Bayer, Amgen, Ipsen, Clovis, Pfizer, Celgene, Novartis, Arcus, Atreca, Bristol Myers Squibb, Mirati, Merus, Abgenomics; Financial Interests, Institutional, Coordinating PI: Boston Biomedical, Incyte; Financial Interests, Institutional, Steering Committee Member: Seattle Genetics; Non-Financial Interests, Advisory Role: Imugene, Sun Biopharma. D. Ahn: Financial Interests, Personal, Speaker, Consultant, Advisor: Genentech, Exelixis, Incyte, Daiichi Sankyo; Financial Interests, Institutional, Research Funding: Bayer, AstraZeneca. C. Yuan, X. Jiao, M. Kurtinecz, X. Pan, Z. Vassilev, H. Ostojic: Financial Interests, Personal, Full or part-time Employment: Bayer.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10